HB Wealth Management LLC Acquires 98 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

HB Wealth Management LLC grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 12.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 869 shares of the biopharmaceutical company’s stock after acquiring an additional 98 shares during the quarter. HB Wealth Management LLC’s holdings in Alnylam Pharmaceuticals were worth $284,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. SVB Wealth LLC bought a new stake in Alnylam Pharmaceuticals during the first quarter worth $27,000. Bessemer Group Inc. grew its holdings in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares in the last quarter. Washington Trust Advisors Inc. grew its holdings in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 61 shares in the last quarter. Steph & Co. bought a new stake in Alnylam Pharmaceuticals during the second quarter worth $60,000. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in Alnylam Pharmaceuticals by 36.1% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 196 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 52 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the topic of several research analyst reports. Royal Bank Of Canada boosted their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, September 19th. HC Wainwright reissued a “buy” rating and issued a $570.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, September 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Saturday, September 27th. Wolfe Research raised Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research report on Monday, August 4th. Finally, Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price objective on the stock. Twenty-four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $448.04.

Insider Buying and Selling

In other news, Director Colleen F. Reitan sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the transaction, the director owned 775 shares in the company, valued at $362,390. This trade represents a 95.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president directly owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,144 shares of company stock worth $44,160,261 over the last quarter. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $452.00 on Tuesday. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The firm has a market capitalization of $59.25 billion, a PE ratio of -183.00 and a beta of 0.36. The business’s 50-day moving average price is $444.12 and its 200-day moving average price is $341.13. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.